Stock listing

Halozyme Therapeutics, Inc.

Selected listing: RV7 · DUS · EUR · DE

Halozyme Therapeutics, Inc. (Dusseldorf:RV7), Health Technology. Latest release Oct 6, 2026: Halozyme Announces Expansion of Global Collaboration and License…

RV7:DUSEURDEUpdated October 2, 2026

Ticker: Dusseldorf:RV7
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Dusseldorf
Currency: EUR

Latest news from Halozyme Therapeutics, Inc.

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

October 6, 2026

Halozyme Announces Appointment of Jim Daly to its Board of Directors

September 30, 2026

Halozyme Announces Appointment of Jim Daly to its Board of Directors

September 29, 2026

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

September 16, 2026

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033

September 16, 2026

All Halozyme Therapeutics, Inc. news →

Events

Replays

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 04:30 PM ET
Watch
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call
Mon, May 11, 2026 · 04:30 PM ET
Watch
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call
Wed, Jan 28, 2026 · 08:30 AM ET
Watch

Research Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. company profile

View the public company page for Halozyme Therapeutics, Inc. on 6ix.

Halozyme Therapeutics, Inc. news

Read company news and market updates connected to Halozyme Therapeutics, Inc..

Halozyme Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Halozyme Therapeutics, Inc..